Charles Schwab
BHVN

Charles Schwab’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Charles Schwab’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-489,030
Closed -$73.9M – 3632
2022
Q3 		$73.9M Sell
489,030
-138,023
-22% -$20.5M 0.03% 557
2022
Q2 		$91.4M Buy
627,053
+23,228
+4% +$2.97M 0.03% 489
2022
Q1 		$71.6M Buy
603,825
+38,955
+7% +$4.86M 0.02% 665
2021
Q4 		$77.8M Buy
564,870
+13,271
+2% +$1.69M 0.02% 646
2021
Q3 		$76.6M Buy
551,599
+152,640
+38% +$19.1M 0.03% 622
2021
Q2 		$38.7M Buy
398,959
+30,353
+8% +$2.46M 0.01% 1059
2021
Q1 		$25.2M Buy
368,606
+24,268
+7% +$1.96M 0.01% 1341
2020
Q4 		$29.5M Buy
344,338
+3,043
+0.9% +$258K 0.01% 1120
2020
Q3 		$22.2M Buy
341,295
+24,684
+8% +$1.62M 0.01% 1136
2020
Q2 		$23.1M Buy
316,611
+29,530
+10% +$1.57M 0.01% 1072
2020
Q1 		$9.77M Buy
287,081
+29,697
+12% +$1.36M 0.01% 1459
2019
Q4 		$14M Sell
257,384
-4,869
-2% -$241K 0.01% 1456
2019
Q3 		$10.9M Buy
262,253
+40,389
+18% +$1.71M 0.01% 1548
2019
Q2 		$9.72M Buy
221,864
+27,903
+14% +$1.57M 0.01% 1605
2019
Q1 		$9.98M Buy
193,961
+16,629
+9% +$718K 0.01% 1589
2018
Q4 		$6.56M Buy
177,332
+19,323
+12% +$697K 0.01% 1733
2018
Q3 		$5.93M Buy
158,009
+19,254
+14% +$708K ﹤0.01% 1956
2018
Q2 		$5.48M Buy
138,755
+51,113
+58% +$1.62M ﹤0.01% 1948
2018
Q1 		$2.26M Buy
87,642
+47,505
+118% +$1.42M ﹤0.01% 2286
2017
Q4 		$1.08M Buy
40,137
+1,872
+5% +$51.5K ﹤0.01% 2486
2017
Q3 		$1.43M Buy
38,265
+1,933
+5% +$58.6K ﹤0.01% 2408
2017
Q2 		$909K Buy
+36,332
New +$837K ﹤0.01% 2487

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Charles Schwab's BHVN Position: Q4 2022 in Review

Charles Schwab sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 489,030 shares — an estimated $73.9M sold.

Charles Schwab first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $91.4M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Charles Schwab reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Charles Schwab sold 489,030 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $73.9M.
  • Charles Schwab first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Charles Schwab's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $91.4M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.